



Supplemental Material

Figure A1. Distribution of claims based on claims history



Note: based on claims history between March 19, 2014 and March 15, 2021.

Figure A2. Number of hospitals per patient based on claims history



Note: based on claims history between March 19, 2014 and March 15, 2021.

Table A1: Drugs for metastatic breast cancer per NCG guidelines

ER + PR + Her 2		HER 2 positive	TNBC
First Line Therapy			
<u>Low tumor burden:</u> Letrozole/ Anastrozole/ Exemestane / Tamoxifen <u>Plus Ribociclib or Palbociclib</u>	<u>Visceral crisis:</u> Taxane	Taxane plus Trastuzumab	Taxane
	Adriamycin Cyclophosphamide (AC) / Epirubicin Cyclophosphamide (EC)		Adriamycin Cyclophosphamide (AC) / Epirubicin Cyclophosphamide (EC) Taxane plus platinum
Second Line Therapy			
Fulvestrant or Everolimus and Exemestane	Capecitabine	Lapatinib plus Capecitabine	Capecitabine
<u>Also in PIK 3 CA mutant - Alpelisib plus Fulvestrant</u>	Gemcitabine Carboplatin	TDM1	Gemcitabine platinum
If premenopausal then Ovarian suppression - Avoid Tamoxifen with Ribociclib		Hormone therapy as maintenance of ER/ PR positive	Eribulin
		-	Olaparib or Rucaparib for any patient with Germline or somatic mutation